Darolutamide cuts prostate cancer recurrence risk by 58%
An Australian-led trial shows results. Adding darolutamide to radiation and hormone therapy greatly reduces the risk of cancer returning or spreading.
The DASL-HiCaP trial tested darolutamide on 1,106 men with very high-risk prostate cancer. Patients got darolutamide plus standard radiation and hormone therapy.
Patients had 58% lower risk of cancer returning, spreading, or death versus standard treatment alone. After 3.8 years, 95% of the darolutamide group stayed cancer-free versus 88% of the standard group.
Researchers say the results could help about 10,900 Australian men each year. The drug is already approved and PBS-listed for advanced prostate cancer.
Trial findings could support using it in earlier-stage cases. Study co-chair Christopher Sweeney said fewer cancer returns ultimately means less death risk from prostate cancer.
Why it mattersHigh-risk prostate cancer patients can now cut their return risk by more than half. A proven treatment improves their chances of surviving long-term.
